Sign in
Taking people in United StatesPhase 1

Tests fecal transplant for bowel side effects of melanoma immunotherapy

Tests gut bacteria transplants for bowel inflammation caused by immunotherapy in melanoma patients.

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Registry title
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Status
Recruiting
Phase
Phase 1
People taking part
800 people, planned
Started
21 Feb 2021
Planned end
31 Oct 2026
Type of study
Interventional
Treatments tested
  • Best Practice
  • Biospecimen Collection
  • Endoscopic Procedure
  • Fecal Microbiota Transplantation
  • Infliximab
  • Laboratory Biomarker Analysis
  • Prednisone
  • Vedolizumab
Record updated
15 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with cancer (melanoma, lung or urinary and genital cancers) treated with immune-checkpoint inhibitor drugs. Some take part with diarrhea or colitis caused by these drugs, and some receive a fecal transplant.

Age
18 years or older
Sex
All sexes can join
Disease stage
Melanoma of any stage, non-small cell lung cancer or genitourinary cancers; any cancer type for projects 2 and 3. Grade 2 or higher drug-related colitis or diarrhea for projects 2 and 3.
Earlier treatment
Must have been treated with an immune-checkpoint inhibitor drug. For the fecal transplant, colitis or diarrhea must not have responded to steroids and other immune-suppressing drugs, must have come back, or those drugs cannot be used.

Main reasons for not taking part

  • Younger than 18 years
  • Inflammatory bowel disease or radiation colitis that is active at the start of treatment
  • Pregnant or breastfeeding women
  • Active bacterial or fungal infection (fecal transplant project)
  • Other side effects outside the gut at the time of the transplant (fecal transplant project)

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Diagnosis of any stage melanoma, Non-Small Cell Lung Cancer or genitourinary (GU) malignancies (Project 1)
  • Diagnosis of any cancer type (Projects 2 and 3)
  • Treatment with any ICPI agent
  • Ability to understand and willingness to sign an informed consent form and rate surveys
  • Life expectancy > 4 months (Project 3)
  • ICPI-related diarrhea and/or colitis of any grade with or without concurrent non- GI toxicity as the toxicity group (project 1)
  • Patients with no organ toxicity as the control group (project 1)
  • ICPI-related colitis and/or diarrhea of grade ≥ 2 as GI toxicity (initial episode or recurrence) receiving standard treatment of immunosuppressive agents (steroid, infliximab, vedolizumab, or ustekinumab) any time during the colitis disease course until sustained resolution of GI toxicity, or one- year time point after enrollment (Project 2)
  • ICPI-related colitis and/or diarrhea of grade ≥ 2 as GI toxicity without involvement of non- GI toxicity within 45 days prior to FMT (Project 3)
  • ICPI-related colitis and/or diarrhea of grade ≥ 2 within 45 days prior to FMT with ANY of the following characteristics (project 3):; (i) refractory to treatment of steroid and two doses of non-steroidal immunosuppressants e.g. infliximab, vedolizumab or ustekinumab,; (ii) contraindication for immunosuppressive treatment,; (iii) recurrence after successful initial treatment,; (iv) recurrent symptoms once steroid is tapered down/off or diarrhea/colitis symptoms are steroid dependent, or; (v) patients with a history of refractory ICPI-related colitis and/or diarrhea to medical treatment, even if they have improved symptoms from supportive care within 45 days prior to FMT
  • No concern for active concomitant GI infection for the ICPI diarrhea/colitis work up at the time of protocol therapy initiation as confirmed by stool tests or as per the treating physician based on clinical presentation (project 3)
  • Patient who has been cleared for enrollment by Infectious Diseases consultant or treating physician if positive infection workup or screening tests (e.g. lifelong positive T-spot due to BCG inoculation, chronic colonization) prior to initiation of diarrhea/colitis treatment (project 3)

Who cannot take part

  • Patients who develop concurrent non- GI toxicity at the time of FMT treatment (project 3)
  • In project 3, if the first 30% of cases fail the fecal transplant treatment, then project 3 will be terminated
  • History of inflammatory bowel disease, and/or radiation enteritis or colitis with active disease status at the time of study treatment initiation
  • Patients with active bacterial or fungal infection (Project 3)
  • Donors at risk for monkeypox infection and/ or exposure as determined by a questionnaire (Project 3); Withdrawal Criteria
  • Patients who develop GI perforation or toxic colitis that require surgery from ICPI colitis
  • Women of child-bearing potential who have positive urine or serum pregnancy test or refuse to do pregnancy test unless last menstrual cycle was > 1 year prior to consent and/ or clear documentation states that patient is peri- or post-menopausal or there was recent supporting objective evidence of 'no pregnancy' status (e.g. blood or imaging) within 30 days prior to date of study treatment
  • Age younger than 18 years
  • Pregnant and breastfeeding women
  • Patients may withdraw from the trial at any time

Where in United States

  • M D Anderson Cancer CenterHouston, United StatesContact: Yinghong WangTaking people

About the trial

What the trial wants to find out

This trial studies the role of the gut microbiome and effectiveness of a fecal transplant on medication-induced gastrointestinal (GI) complications in patients with melanoma or genitourinary cancer. The gut microbiome (the bacteria and microorganisms that live in the digestive system) may affect whether or not someone develops colitis (inflammation of the intestines) during cancer treatment with immune-checkpoint inhibitor drugs. Studying samples of stool, blood, and tissue from patients with melanoma or genitourinary cancer may help doctors learn more about the effects of treatment on cells, and help doctors understand how well patients respond to treatment. Treatment with fecal transplantation may help to improve diarrhea and colitis symptoms.

The group in the trial

  • Supportive Care (standard of care, sample collection, FMT)Treatment being tested

    PROJECT 1: Patients receive standard of care and undergo collection of stool and blood samples. PROJECT 2: Patients receive prednisone, infliximab, or vedolizumab per standard of care and undergo standard of care endoscopy 2 months after treatment. Patients also undergo collection of stool, blood, and tissue samples. PROJECT 3: Patients undergo FMT.

    Treatment: Best Practice, Biospecimen Collection, Endoscopic Procedure, Fecal Microbiota Transplantation, Infliximab, Laboratory Biomarker Analysis, Prednisone, and Vedolizumab

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Role of Microbiome in the Realm of Immune-Checkpoint Inhibitor Induced GI Complications In Cancer Population
Plain-language title
Tests fecal transplant for bowel side effects of melanoma immunotherapyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
15 July 2026